Study guide

3.3 Neuromuscular Blockade - Depolarizing vs Non-Depolarizing Agents

IBSC CCP-C Certified Critical Care Paramedic Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Strategy

1.1 About the CCP-C Exam 1.2 CCP-C Study Strategy & Exam Tactics

2 Chapter 2: Transport and Safety (Part 1)

2.1 Crew Resource Management & Sterile Cockpit Rule 2.2 Transport Risk Assessment & Mission Decision-Making 2.3 Aircraft and Ground Transport Safety Protocols

3 Chapter 2: Transport and Safety (Part 2)

2.4 Environmental Transport Stressors & Gas Laws 2.5 Transport Equipment Management & Post-Mission Operations

4 Chapter 3: Airway, Anesthesia, and Analgesics (Part 1)

3.1 Advanced Airway Assessment & Difficult Airway Identification 3.2 Rapid Sequence Induction (RSI) - Pretreatment & Induction Agents 3.3 Neuromuscular Blockade - Depolarizing vs Non-Depolarizing Agents 3.4 Post-Intubation Sedation, Analgesia & Dissociative Maintenance 3.5 Transport Ventilator Setup & Primary Ventilation Modes

5 Chapter 3: Airway, Anesthesia, and Analgesics (Part 2)

3.6 Mechanical Ventilator Waveforms, Loops & Oxygenation Titration 3.7 Ventilator Alarm Troubleshooting & Peak vs Plateau Pressures 3.8 Rescue Airway Devices, Video Laryngoscopy & Surgical Cricothyrotomy 3.9 Neuromuscular Reversal & Vasoactive Airway Support 3.10 Transport Airway Management in Unique Environments & Extubation

6 Chapter 4: General Medical Patient

4.1 Sepsis, Severe Sepsis & Septic Shock Resuscitation 4.2 Endocrine Emergencies (DKA, HHS, Adrenal Crisis, Thyroid Storm) 4.3 Renal and Hepatic Emergencies in Transport

7 Chapter 5: Cardiac Patient

5.1 Acute Coronary Syndromes & Infarct Specific Complications 5.2 Invasive Hemodynamic Monitoring 5.3 Vasoactive & Inotropic Medication Titration 5.4 Mechanical Circulatory Support & Post-Cardiac Arrest Care

8 Chapter 6: Neurological Patient

6.1 Traumatic Brain Injury & Intracranial Pressure (ICP) Management 6.2 Acute Ischemic Stroke, Hemorrhagic Stroke & Subarachnoid Hemorrhage 6.3 Status Epilepticus, Spinal Cord Injury & Neurogenic Shock

9 Chapter 7: Respiratory Patient

7.1 Acute Respiratory Distress Syndrome (ARDS) & Lung-Protective Ventilation 7.2 Severe Asthma & COPD Exacerbations in Critical Care 7.3 Chest Tube Management, Pleural Drains & Tension Pneumothorax 7.4 Pulmonary Embolism, Pulmonary Hypertension & Transport Respiratory Meds

10 Chapter 8: Toxic Exposure and Environmental Patient

8.1 Toxicology Emergencies, Toxidromes & Antidote Therapy 8.2 Environmental Emergencies (Hypothermia, Hyperthermia, Frostbite) 8.3 Submersion, Diving Emergencies & Envenomation/HazMat

11 Chapter 9: Trauma and Burn Patient

9.1 Hemorrhagic Shock Resuscitation & Massive Transfusion Protocols (MTP) 9.2 Severe Thoracic & Abdominal Trauma Management 9.3 Thermal, Chemical & Electrical Burn Assessment & Fluid Resuscitation 9.4 Musculoskeletal Trauma, Pelvic Fractures & Compartment Syndrome

12 Chapter 10: Maternal and Fetal Medicine

10.1 High-Risk Obstetric Assessment & Hypertensive Disorders of Pregnancy 10.2 Obstetric Hemorrhage, Placental Abruption & Preterm Labor 10.3 Emergency Transport Delivery, Umbilical Cord Prolapse & Fetal Monitoring

13 Chapter 11: Pediatric Patient

11.1 Pediatric Critical Care Airway & Transport Ventilation 11.2 Pediatric Shock, Dehydration & Weight-Based Dosing 11.3 Neonatal Resuscitation Program (NRP) & Transport of the Critical Neonate

14 Chapter 12: Special Populations

12.1 Bariatric Critical Care Transport & Positional Management 12.2 Geriatric Critical Care & Patients with Specialized Medical Technology

15 Chapter 13: Professional Considerations

13.1 Legal Aspects, EMTALA & Transport Ethics 13.2 Quality Improvement, Transport Safety Research & Evidence-Based Practice

3.3 Neuromuscular Blockade - Depolarizing vs Non-Depolarizing Agents

Key Takeaways Explain This Topic AI

Succinylcholine (1.5–2.0 mg/kg IV) is the sole depolarizing neuromuscular blocker, offering ultra-rapid onset (45–60 sec) and short duration (6–10 min), but poses life-threatening hyperkalemia risks.

Succinylcholine causes a baseline serum potassium surge of 0.5–1.0 mEq/L and is strictly contraindicated in denervation injuries (>24–48 hours post-event), major burns (>24–48 hours), crush injuries, muscular dystrophies, or known hyperkalemia.

Malignant Hyperthermia (MH) is a life-threatening hypermetabolic crisis triggered by succinylcholine; early signs include a sudden unexplained surge in ETCO2 and masseter spasm, treated immediately with Dantrolene (2.5 mg/kg IV).

Rocuronium (1.0–1.2 mg/kg IV RSI dose) is a non-depolarizing competitive nicotinic antagonist that achieves paralysis in 60 seconds with a 45–70 minute duration and no hyperkalemia or MH risk.

Sugammadex (Bridion) provides specific 1:1 encapsulation reversal of rocuronium, dosed at 2 mg/kg for shallow block, 4 mg/kg for deep block, and 16 mg/kg for immediate emergency reversal post-RSI.

Last updated: July 2026

Neuromuscular Blockade — Depolarizing vs Non-Depolarizing Agents

Neuromuscular blocking agents (NMBAs) are essential components of Rapid Sequence Induction. By binding to nicotinic acetylcholine ( A C h ACh A C h ) receptors at the motor endplate of the neuromuscular junction, NMBAs produce complete skeletal muscle paralysis. Transport paramedics must understand the functional differences between depolarizing and non-depolarizing paralytics, as misapplication in high-risk patient populations can precipitate fatal hyperkalemic cardiac arrest or trigger hypermetabolic crises.

  • 1. Depolarizing Neuromuscular Blockers
  • Succinylcholine Chloride (Anectine)

Mechanism of Action: Succinylcholine consists of two linked acetylcholine molecules. It binds to post-synaptic nicotinic A C h ACh A C h receptors at the neuromuscular junction, causing persistent endplate depolarization. This initially manifests as transient muscle twitching ( fasciculations ), followed by flaccid paralysis because the voltage-gated sodium channels become inactivated and cannot repolarize.

RSI Dosing: 1.5 − 2.0 mg/kg IV 1.5 - 2.0\text{ mg/kg IV} 1.5 − 2.0 mg/kg IV (use 2.0 mg/kg IV 2.0\text{ mg/kg IV} 2.0 mg/kg IV in obese patients or 2.0 mg/kg 2.0\text{ mg/kg} 2.0 mg/kg in pediatrics to ensure rapid glottic relaxation).

Onset & Duration: Onset 45 − 60 seconds 45 - 60\text{ seconds} 45 − 60 seconds ; Duration 6 − 10 minutes 6 - 10\text{ minutes} 6 − 10 minutes .

Metabolism: Rapidly hydrolyzed in plasma by plasma pseudocholinesterase (butyrylcholinesterase). Only a small fraction of the injected dose reaches the neuromuscular junction.

Pathophysiology of Extrajunctional Receptors & Hyperkalemia

In normal skeletal muscle, succinylcholine administration causes a transient release of intracellular potassium, elevating serum potassium ( K + K^+ K + ) by 0.5 − 1.0 mEq/L 0.5 - 1.0\text{ mEq/L} 0.5 − 1.0 mEq/L . However, in specific pathological states, skeletal muscle undergoes extrajunctional acetylcholine receptor upregulation (alpha-7 cholinergic subunit proliferation spread across the entire muscle cell membrane). When succinylcholine binds to these extrajunctional receptors, massive, uncoordinated potassium efflux occurs, precipitating severe, refractory hyperkalemia and cardiac arrest within minutes.

Absolute Contraindications for Succinylcholine:

Denervation Injuries ( > 24 − 48 hours > 24-48\text{ hours} > 24 − 48 hours post-event): Stroke, spinal cord injury, spinal muscular atrophy, or peripheral nerve transection.

Major Thermal Burns ( > 24 − 48 hours > 24-48\text{ hours} > 24 − 48 hours post-injury): Extrajunctional receptor expression persists until full tissue healing/grafting occurs (up to 1–2 years).

Severe Crush Injuries or Compartment Syndrome ( > 24 − 48 hours > 24-48\text{ hours} > 24 − 48 hours ): Massive muscle necrosis and receptor upregulation.

Chronic Muscular Dystrophies: Duchenne or Becker muscular dystrophy (high risk of rhabdomyolysis and hyperkalemic cardiac arrest).

Pre-existing Severe Hyperkalemia: Known K + > 5.5 mEq/L K^+ > 5.5\text{ mEq/L} K + > 5.5 mEq/L or characteristic ECG changes (peaked T waves, QRS widening).

Personal or Family History of Malignant Hyperthermia.

Plasma Pseudocholinesterase Deficiency: Genetic variant causing prolonged paralysis lasting several hours.

2. Malignant Hyperthermia (MH)

Malignant Hyperthermia is a rare, life-threatening pharmacogenetic autosomal dominant disorder of skeletal muscle triggered by succinylcholine or volatile halogenated anesthetic gases (e.g., sevoflurane, isoflurane).

Pathophysiology

An inherited mutation in the Ryanodine Receptor Type 1 (RYR1) gene impairs calcium channel regulation in the sarcoplasmic reticulum. Exposure to trigger agents causes an uncontrolled surge of calcium into the myoplasm, producing sustained muscle contraction, extreme hypermetabolism, ATP depletion, and cellular destruction.

Clinical Presentation Sequence

Earliest Sign: Unexplained, rapid surge in End-Tidal C O 2 CO_2 C O 2 ​ ( E T C O 2 ETCO_2 ETC O 2 ​ ) resistant to mechanical hyperventilation.

Masseter Muscle Spasm (Trismus): Rigid jaw muscle contraction immediately following succinylcholine administration.

Skeletal Muscle Rigidity: Total body "board-like" rigidity.

Tachycardia & Hyperdynamic Instability: Marked sinus tachycardia, tachypnea, and unstable blood pressure.

Metabolic & Respiratory Acidosis: Severe mixed acidosis with profound base deficit and hyperlactatemia.

Hyperthermia (Late Sign): Core body temperature rising as fast as 1 − 2 ∘ C 1-2^\circ\text{C} 1 − 2 ∘ C every 5 minutes (can exceed 42 ∘ C / 107 ∘ F 42^\circ\text{C} / 107^\circ\text{F} 4 2 ∘ C /10 7 ∘ F ).

Rhabdomyolysis & Hyperkalemia: Myoglobinuria (dark brown urine), severe hyperkalemia, DIC, and acute kidney injury.

Emergency Management Protocol for Malignant Hyperthermia

Stop Triggers: Immediately discontinue succinylcholine/volatile anesthetics.

Hyperventilate: Administer 100% O 2 O_2 O 2 ​ at maximum flow rates with high minute ventilation to clear C O 2 CO_2 C O 2 ​ .

Administer Dantrolene Sodium:

Dose: 2.5 mg/kg IV 2.5\text{ mg/kg IV} 2.5 mg/kg IV rapid push bolus , repeated every 5–10 minutes until symptoms subside (up to maximum cumulative dose of 10 mg/kg 10\text{ mg/kg} 10 mg/kg ). Reconstitute each 20 mg vial with 60 mL sterile water.

Mechanism: Direct skeletal muscle relaxant that binds to the RYR1 receptor, blocking calcium release from the sarcoplasmic reticulum.

Active Cooling: Apply ice packs to groin, axillae, and neck; perform cold IV fluid resuscitation until core temp drops < 38.5 ∘ C < 38.5^\circ\text{C} < 38. 5 ∘ C .

Treat Hyperkalemia & Acidosis: Administer Sodium Bicarbonate ( 1 mEq/kg 1\text{ mEq/kg} 1 mEq/kg ), Calcium Chloride ( 1 g IV 1\text{ g IV} 1 g IV ), Insulin + Dextrose.

3. Non-Depolarizing Neuromuscular Blockers

Non-depolarizing NMBAs act as competitive antagonists at post-synaptic nicotinic A C h ACh A C h receptors. They do not cause endplate depolarization, fasciculations, potassium release, or Malignant Hyperthermia.

Rocuronium Bromide (Zemuron)

Class: Aminosteroid non-depolarizing NMBA.

RSI Dose: 1.0 − 1.2 mg/kg IV 1.0 - 1.2\text{ mg/kg IV} 1.0 − 1.2 mg/kg IV (Note: Standard non-RSI intubation dose is 0.6 mg/kg 0.6\text{ mg/kg} 0.6 mg/kg , but 1.2 mg/kg 1.2\text{ mg/kg} 1.2 mg/kg is required in RSI to achieve glottic paralysis within 60 seconds).

Onset & Duration: Onset 60 seconds 60\text{ seconds} 60 seconds ; Duration 45 − 70 minutes 45 - 70\text{ minutes} 45 − 70 minutes (can extend beyond 90 minutes in hypothermic or elderly patients).

Advantages: No hyperkalemia risk, no MH risk, excellent intubating conditions comparable to succinylcholine. Ideal paralytic of choice in neurotrauma, burns, and renal failure.

Vecuronium Bromide (Norcuron)

Class: Aminosteroid non-depolarizing NMBA.

RSI Dose: 0.1 − 0.15 mg/kg IV 0.1 - 0.15\text{ mg/kg IV} 0.1 − 0.15 mg/kg IV (Must be reconstituted from powder form).

Onset & Duration: Onset 2.5 − 3.0 minutes 2.5 - 3.0\text{ minutes} 2.5 − 3.0 minutes (significantly slower than rocuronium); Duration 30 − 45 minutes 30 - 45\text{ minutes} 30 − 45 minutes .

Clinical Application: Suboptimal for primary RSI intubation due to prolonged onset time, but commonly utilized for continuous post-intubation paralysis maintenance.

4. Reversal Pharmacology: Sugammadex

Sugammadex (Bridion) represents a breakthrough in non-depolarizing neuromuscular blockade reversal.

Mechanism of Action: Modified γ \gamma γ -cyclodextrin molecule with a lipophilic core that selectively encapsulates rocuronium (and vecuronium) molecules in a 1:1 ratio in plasma. This creates a concentration gradient, drawing the drug off the nicotinic receptors back into the vascular space for renal excretion.

Dosing Guidelines:

2 mg/kg IV 2\text{ mg/kg IV} 2 mg/kg IV : Routine reversal for moderate block (reappearance of 2 twitches on Train-of-Four [TOF] monitoring).

4 mg/kg IV 4\text{ mg/kg IV} 4 mg/kg IV : Reversal for deep block (1–2 post-tetanic counts [PTC]).

16 mg/kg IV 16\text{ mg/kg IV} 16 mg/kg IV : Immediate emergency reversal administered 3 minutes after an RSI dose of Rocuronium ( 1.2 mg/kg 1.2\text{ mg/kg} 1.2 mg/kg ). Reverses paralysis within 2 to 3 minutes during a CICO crisis.

Traditional Reversal Alternative: Neostigmine ( 0.04 − 0.07 mg/kg IV 0.04 - 0.07\text{ mg/kg IV} 0.04 − 0.07 mg/kg IV ) combined with Glycopyrrolate ( 0.01 mg/kg IV 0.01\text{ mg/kg IV} 0.01 mg/kg IV ) or Atropine. Neostigmine inhibits acetylcholinesterase, increasing A C h ACh A C h concentration. Crucial limitation: Neostigmine cannot reverse a deep neuromuscular block (TOF must show at least 2 twitches) and takes 10–20 minutes to work.

Neuromuscular Blocking Agents Comparison

  • Feature Succinylcholine Rocuronium Vecuronium
  • Drug Class Depolarizing Non-Depolarizing (Aminosteroid) Non-Depolarizing (Aminosteroid)

RSI Dose 1.5 − 2.0 mg/kg IV 1.5-2.0\text{ mg/kg IV} 1.5 − 2.0 mg/kg IV 1.0 − 1.2 mg/kg IV 1.0-1.2\text{ mg/kg IV} 1.0 − 1.2 mg/kg IV 0.1 − 0.15 mg/kg IV 0.1-0.15\text{ mg/kg IV} 0.1 − 0.15 mg/kg IV

Paralytic Onset 45 − 60 seconds 45-60\text{ seconds} 45 − 60 seconds 60 seconds 60\text{ seconds} 60 seconds 150 − 180 seconds 150-180\text{ seconds} 150 − 180 seconds

Duration of Action 6 − 10 minutes 6-10\text{ minutes} 6 − 10 minutes 45 − 70 minutes 45-70\text{ minutes} 45 − 70 minutes 30 − 45 minutes 30-45\text{ minutes} 30 − 45 minutes

  • Fasciculations Yes No No
  • Hyperkalemia Risk High ( + 0.5 − 1.0 mEq/L +0.5-1.0\text{ mEq/L} + 0.5 − 1.0 mEq/L baseline) None None
  • Malignant Hyperthermia Trigger Agent No Risk No Risk

Reversal Agent None (Plasma pseudocholinesterase) Sugammadex ( 2 − 16 mg/kg 2-16\text{ mg/kg} 2 − 16 mg/kg ) Sugammadex / Neostigmine